14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ATRS ranks #14334 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$3.35 (0.30%)

Volume: 430k

Closed: Dec 08, 2021

Hollow Logo Score: -2.746

Antares Pharma Stock Forecast

$3.35 (0.30%)

Volume: 430k

Closed: Dec 08, 2021

Score Hollow Logo -2.746
Which way will ATRS go? Request
Key Stats
P/E Ratio 8.74
Beta 1.05
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 44 and the stock is currently not being overbought or oversold

Antares Pharma stock price ended on $3.35 on Wednesday after gaining 0.3%
(Updated on Dec 08, 2021)


Sell candidate since 2021-11-10 Loss -11.38%

The Antares Pharma stock price gained 0.30% on the last trading day (Wednesday, 8th Dec 2021), rising from $3.34 to $3.35. , and has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 1.96% from a day low at $3.32 to a day high of $3.39. The price has been going up and down for this period, and there has been a -1.76% loss for the last 2 weeks. Volume fell on the last day by -40 thousand shares and in total, 430 thousand shares were bought and sold for approximately $1.44 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -8.19% during the next 3 months and, with a 90% probability hold a price between $2.88 and $3.48 at the end of this 3-month period.

Signals & Forecast

There are mixed signals in the stock today. The Antares Pharma stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $3.54. On a fall, the stock will find some support from the short-term average at $3.25. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not. A buy signal was issued from a pivot bottom point on Friday, December 03, 2021, and so far it has risen 6.35%. Further rise is indicated until a new top pivot has been found.

Support, Risk & Stop-loss

Antares Pharma finds support from accumulated volume at $3.26 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0650 between high and low, or 1.96%. For the last week the stock has had a daily average volatility of 3.88%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Antares Pharma stock A Buy?

Antares Pharma holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.746

Predicted Opening Price for Antares Pharma of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$3.35 $3.35 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 05, 2021 "HC Wainwright" gave "$6.00 - $5.00" rating for ATRS. The price target was set to $3.77+3.0%.

Volatility and Risk
Daily Average Volatility: 3.88 %
Overall Risk: Very High High Medium Low Very Low
Volatility
3.88 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $3.54
Price: $3.35
Support: $3.26

ATRS Insider Trading Show all Trades

INSIDER POWER

1.850

Last 100 transactions
Buy: 3 908 094 | Sell: 2 112 499 (Shares)
Date Action Amount Person Type
Oct 27, 2021 Buy 55 916 Volkart Carmen B Stock Option (right to buy)
Aug 27, 2021 Sell 13 820 Jacob Leonard S Common Stock
Aug 27, 2021 Buy 24 679 Jacob Leonard S Stock Option (right to buy)
Aug 27, 2021 Buy 24 679 Jacob Leonard S Common Stock
Jul 08, 2021 Sell 100 000 Gueth Anton Common Stock
Show all Insider Trades
INSIDER POWER

1.850

Last 100 transactions
Buy: 3 908 094 | Sell: 2 112 499 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 3.42 1.99 %
3.39 1.25 %
3.38 0.79 %
Current price: 3.35
Support 3.33 -0.69 %
3.31 -1.15 %
3.29 -1.89 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 3.74 11.64 %
3.66 9.25 %
3.54 5.67 %
Current price 3.35
Support 3.26 -2.69%
3.23 -3.58%
3.18 -5.07%

Click to get the best stock tips daily for free!

About Antares Pharma

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; ZOMA-Jet and Twin-Jector, a needle-free a... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT